|
|
|
|
|
|
最高研发阶段药物发现 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
Open-label, Dose Confirmation Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Glioblastoma Multiforme (GBM) at First Relapse
Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus literally destroys the tumor "from the inside out". This may be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer.
100 项与 组蛋白H1 x DNA 相关的临床结果
100 项与 组蛋白H1 x DNA 相关的转化医学
0 项与 组蛋白H1 x DNA 相关的专利(医药)